发布求助
文献互助 智能选刊 最新文献

Clinical Advances in Hematology & Oncology最新文献

筛选
英文 中文
Integration of immunotherapy into the frontline treatment of acute lymphoblastic leukemia. 将免疫疗法纳入急性淋巴细胞白血病的一线治疗。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2025-09-01
Ajoy Dias, Mark R Litzow
{"title":"Integration of immunotherapy into the frontline treatment of acute lymphoblastic leukemia.","authors":"Ajoy Dias, Mark R Litzow","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Immunotherapy has transformed the treatment of acute lymphoblastic leukemia (ALL) over the past 2 decades, leading to excellent outcomes in adults and children. This is especially true in the setting of relapsed and refractory (R/R) disease, in which treatment outcomes formerly were dismal. Several immune therapies have shown efficacy and safety in the R/R setting, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and chimeric antigen receptor (CAR) T-cell therapy. These new immunotherapy approaches have brought about a major paradigm shift in the treatment of R/R ALL, with very few long-term side effects in comparison with standard chemotherapy. These agents are now being used in patients with newly diagnosed ALL, with good response rates. This review discusses novel immunotherapeutic options, including bispecific antibodies, ADCs, and CAR T-cell-based therapies, in the upfront setting. It also discusses the incorporation of novel agents either as monotherapy or in combination with cytotoxic chemotherapy and describes our views on how best to use these agents in patients with newly diagnosed disease.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 6","pages":"350-360"},"PeriodicalIF":1.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145115008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Midyear highlights in gastrointestinal cancers. 年中以胃肠道癌为主。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2025-09-01
{"title":"Midyear highlights in gastrointestinal cancers.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 Suppl 9 6","pages":"1-18"},"PeriodicalIF":1.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145114936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FDA regulatory pathways for expedited drug development and approval. FDA加快药物开发和批准的监管途径。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2025-09-01
Aaron S Kesselheim
{"title":"FDA regulatory pathways for expedited drug development and approval.","authors":"Aaron S Kesselheim","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 6","pages":"382-384"},"PeriodicalIF":1.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145114939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The addition of darolutamide to androgen deprivation therapy in metastatic hormone-sensitive prostate cancer. 在转移性激素敏感前列腺癌的雄激素剥夺治疗中加入达洛鲁胺。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2025-07-01
Fred Saad
{"title":"The addition of darolutamide to androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.","authors":"Fred Saad","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 5","pages":"307-309"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144735220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Highlights in upper gastrointestinal cancer from the 2025 American Society of Clinical Oncology Annual Meeting. 2025年美国临床肿瘤学会年会上上消化道肿瘤的亮点。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2025-07-01
{"title":"Highlights in upper gastrointestinal cancer from the 2025 American Society of Clinical Oncology Annual Meeting.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 5","pages":"317-319"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144735215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Revolutionizing breast cancer treatment: the promise of antibody-drug conjugates. 革命性的乳腺癌治疗：抗体-药物结合物的前景。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2025-07-01
Samer Alkassis, John A Glaspy, Aditya Bardia
{"title":"Revolutionizing breast cancer treatment: the promise of antibody-drug conjugates.","authors":"Samer Alkassis, John A Glaspy, Aditya Bardia","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Antibody-drug conjugates (ADCs) have significantly advanced the treatment of breast cancer by integrating the specificity of monoclonal antibodies with the cytotoxic efficacy of chemotherapy, thereby enabling a targeted therapeutic approach that reduces off-target toxicity to normal tissues. Currently, 4 ADCs-sacituzumab govitecan, trastuzumab deruxtecan, trastuzumab emtansine, and the more-recent datopotamab deruxtecan-are approved for clinical application, with several others in advanced stages of development. Although these agents have demonstrated promising clinical efficacy, challenges such as ADC resistance and associated toxicities have emerged, underscoring the need for continued research. Multiple strategies are under investigation to enhance therapeutic benefit through combination regimens with other classes of medications, as are approaches to mitigate resistance mechanisms. Progress in next-generation ADCs, incorporating novel linkers and more potent cytotoxic payloads, holds promise for further improvement in clinical outcomes. Additionally, biomarker-driven strategies to identify those patients most likely to benefit from ADC therapy will support more personalized approaches to treatment. This review explores the structural and mechanistic features of ADCs in breast cancer, highlighting their therapeutic potential, and discusses ongoing clinical trials exploring new-generation ADCs and combination therapies.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 5","pages":"290-299"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144735218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First-line use of antiangiogenic agents in unresectable hepatocellular carcinoma: a double-edged sword? 抗血管生成药物在不可切除的肝细胞癌中的一线应用：双刃剑？
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2025-07-01
Aditya Mahadevan, Armon Azizi, Nadine Abi-Jaoudeh, Jennifer Valerin, April Choi, Harry Nguyen, Farshid Dayyani
{"title":"First-line use of antiangiogenic agents in unresectable hepatocellular carcinoma: a double-edged sword?","authors":"Aditya Mahadevan, Armon Azizi, Nadine Abi-Jaoudeh, Jennifer Valerin, April Choi, Harry Nguyen, Farshid Dayyani","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Treatment options for hepatocellular carcinoma (HCC), the most prevalent primary liver malignancy, have historically been limited, particularly in unresectable cases with underlying cirrhosis. Initial systemic therapy with antiangiogenic agents, notably vascular endothelial growth factor (VEGF) inhibitors such as sorafenib, showed modest survival gains but lacked durable responses. Subsequent trials with more potent VEGF pathway inhibitors failed to improve overall survival significantly, raising concerns about the long-term utility and potential hepatic and renal toxicities of prolonged VEGF blockade. The advent of immune checkpoint inhibitors (ICIs) marked a paradigm shift. Trial results demonstrating that dual-ICI regimens induced more durable responses and achieved higher long-term survival rates have challenged the prior VEGF-centric therapeutic approach and suggest that early use of dual ICIs may offer a more transformative effect on disease trajectory. Although anti-VEGF therapies remain valuable for initial tumor shrinkage, prolonged use may compromise liver regeneration and worsen portal hypertension. A refined treatment strategy emphasizing VEGF inhibition for a limited duration followed by or combined with ICIs may optimize both efficacy and safety. Future research should focus on identifying predictive biomarkers for ICI response and on developing regimens that maximize long-term survival in unresectable HCC.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 5","pages":"301-306"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144735214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reducing drug toxicity and costs through off-label dosing. 通过超说明书剂量降低药物毒性和成本。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2025-07-01
Mark J Ratain
{"title":"Reducing drug toxicity and costs through off-label dosing.","authors":"Mark J Ratain","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 5","pages":"328-330"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144735217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is doublet therapy becoming a standard of care in myelofibrosis? 双重治疗正在成为骨髓纤维化的标准治疗吗？
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2025-07-01
Raajit K Rampal
{"title":"Is doublet therapy becoming a standard of care in myelofibrosis?","authors":"Raajit K Rampal","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 5","pages":"320-322"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144735216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sequencing antibody-drug conjugates in patients with hormone receptor-positive, HER2-negative metastatic breast cancer. 激素受体阳性her2阴性转移性乳腺癌患者的抗体-药物偶联物测序
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2025-07-01
Javier Cortés
{"title":"Sequencing antibody-drug conjugates in patients with hormone receptor-positive, HER2-negative metastatic breast cancer.","authors":"Javier Cortés","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 5","pages":"331-333"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144735219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信